NEW YORK – Revel Health and Coriell Life Sciences (CLS) said on Tuesday that they have partnered to help Medicare Advantage members take advantage of DNA testing to determine prescription drug efficacy.
Using Revel Connect, Revel Health's health action platform, the partners will communicate and promote CLS's genetic testing offering to Medicare Advantage members. Revel Health and CLS launched the first wave of the program in June to reach more than 22,000 members.
Philadelphia-based CLS offers a number of precision medicine products and services including a pharmacogenomics (PGx) service that evaluates patient genetics alongside other medication-associated risks to improve patient health and inform medication safety and efficacy.
Last year CLS partnered with KPMG and Thermo Fisher Scientific to provide PGx data to clinicians at the point of care. CLS also has a partnership with RxGenomix to offer PGx training, implementation, and management to healthcare providers.
Revel Health, based in Minneapolis, helps healthcare organizations connect with members and patients primarily through its Revel Connect platform, which uses data science, behavioral research, and multi-channel tools to help personalize the communication and delivery of DNA testing products and services.
"We're excited to work with Coriell Life Sciences on this new initiative to empower members to take action to understand how medications personally impact them," Revel Health CEO Jeff Fritz said in a statement. "CLS is committed to helping members understand how their genes can impact a response to certain medications, and this commitment shows in their desire to use the latest tools and techniques in driving healthier action."